{
    "nctId": "NCT00104624",
    "briefTitle": "Docetaxel in Treating Older Women With Metastatic Breast Cancer",
    "officialTitle": "Phase II Trial Assessing the Impact on Instrumental and Daily Living Autonomy of a Chemotherapy With Biweekly Docetaxel in the Treatment of Metastatic Breast Cancer in Patients Over 70",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "N/A",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 53,
    "primaryOutcomeMeasure": "Degree of autonomy in instrumental activities of daily living as measured by Lawton's Instrumental Activities of Daily Living Scale during therapy and at 6 and 12 months",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed adenocarcinoma of the breast\n\n  * Metastatic disease\n* Measurable disease by CT scan or MRI\n* Requires first-line chemotherapy for metastatic disease\n* Hormone receptor status:\n\n  * Not specified\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* 70 and over\n\nSex\n\n* Female\n\nMenopausal status\n\n* Not specified\n\nPerformance status\n\n* Meets both of the following criteria:\n\n  * Lawton's Instrumental Activities of Daily Living score \u2265 4\n  * Katz's Activities of Daily Living score \u2265 4\n\nLife expectancy\n\n* More than 3 months\n\nHematopoietic\n\n* Hemoglobin \\> 10 g/dL\n* Neutrophil count \\> 1,500/mm\\^3\n* Platelet count \\> 100,000/mm\\^3\n\nHepatic\n\n* ALT and AST \\< 1.5 times normal\n* Bilirubin normal\n* Alkaline phosphatase \\< 2.5 times normal\n\nRenal\n\n* Creatinine clearance \\> 30 mL/min\n\nCardiovascular\n\n* No congestive heart failure\n* No unstable angina pectoris\n* No myocardial infarction within the past year\n* No uncontrolled hypertension\n* No high-risk uncontrolled arrhythmias\n\nOther\n\n* Geriatric Depression Score \\< 12\n* No active uncontrolled infection\n* No active peptic ulcer\n* No uncontrolled diabetes mellitus\n* No inflammatory bowel disease\n* No history of hypersensitivity to docetaxel or drugs formulated with polysorbate 80\n* No history of significant neurologic or psychiatric disorders, including psychotic disorders, dementia, or seizures, that would preclude giving informed consent\n* No familial, social, geographical, or psychological condition that would preclude study follow-up\n* No definite contraindication to corticosteroids\n* No other serious illness or medical condition\n* No other malignancy within the past 5 years except basal cell skin cancer or carcinoma in situ of the cervix\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* No prior or concurrent trastuzumab (Herceptin\\^\u00ae)\n\nChemotherapy\n\n* Prior neoadjuvant or adjuvant chemotherapy for breast cancer allowed\n* More than 2 years since prior docetaxel or paclitaxel\n* No other concurrent chemotherapy\n\nEndocrine therapy\n\n* No more than 1 prior hormonal therapy regimen for metastatic disease\n* At least 10 days since prior hormonal therapy\n* No concurrent hormonal therapy\n* No concurrent chronic corticosteroids\n\n  * Concurrent low-dose corticosteroids (\u2264 20 mg/day of methylprednisolone or equivalent) allowed provided treatment was initiated \\> 6 months before study entry\n\nRadiotherapy\n\n* Not specified\n\nSurgery\n\n* Not specified\n\nOther\n\n* More than 30 days since prior active treatment on another clinical trial\n* Concurrent bisphosphonates allowed for bone metastases, osteoporosis, or osteopenia\n* No other concurrent anticancer therapy\n* No other concurrent investigational drugs",
    "sex": "FEMALE",
    "minimumAge": "70 Years",
    "stdAges": "OLDER_ADULT"
}